Institute for Cancer Research


Institute for Cancer Research has since its foundation in 1954 played a central role within the field of cancer research both in Norway and internationally. The Institute has seven research departments and more than 320 employees, master students included. About 70% of the employees and projects are externally funded.

The Institute has internationally strong research groups within biochemistry, cell and tumor biology, genetics, radiation biology, immunology and cancer prevention. For more than 30 years there has been a close interaction between researchers at the Institute and cancer surgeons, oncologists and pathologists. This emphasis on translational science has resulted in numerous clinical protocols based on in-house research, and the Institute is a key partner in the Comprehensive Cancer Center, organizationally under the Division of Surgery and Cancer Treatment at Oslo University Hospital.

Gunnar Sæter<br>Scientific director
Gunnar Sæter
Scientific director

Scientific production - Institute for Cancer Research

  Publications Doctoral theses
 2016  so far  
2015 220 21
2014 176 25
2013 197 27
2012 175 18
2011 201 22

Annual report 2015 (pdf format)


Latest news

Institute seminar Wednesday September 28th at 12:00 in the Auditorium

Dr. Bastian Fromm – Postdoc in Flatmark group

Bastian Fromm
Bastian Fromm

The first Institute seminar this autumn will take place Wednesday 28th of September at 12:00 in the auditorium. For this session we have the following speaker:
Dr. Bastian Fromm – Postdoc in Flatmark group at Department of Tumor Biology
Title of his talk: “TAMING THE BEAST - towards a bioinformatics tool shed for microRNA analysis in cancer”


Paper from Dahl/Klungland published in the Sep 22nd issue of Nature

Histone marks regulate maternal-to-zygotic transition

John Arne Dahl<br>First author
John Arne Dahl
First author

John Arne Dahl (photo), from Department of Microbiology has published a collaborative study entitled "Broad histone H3K4me3 domains in mouse oocytes modulate maternal-to-zygotic transition", in the 22nd September issue of Nature (journal impact factor 41.5).

The study was carried out together with the lab of Arne Klungland, Department of Microbiology, and Bing Ren, University of California and Ludwig Institute for Cancer Research, San Diego.


Marina Vietri interviewed for major Italian research web portal

Marina Vietri (photo ResearchItaly)
Marina Vietri (photo ResearchItaly)

A comprehensive interview with postdoc Marina Vietri from Harald Stenmark's group at the Department of Molecular Biology has recently been published on - the web portal of the Italian Ministry of Education, University and Research (MIUR) established in order to map, support and promote high-quality Italian research.
The introduction to the English version of this readable interview goes as follows: "From San Raffaele in Milan to the Institute for Cancer Research of the University Hospital of Oslo where her research deserved publication in Nature and she won the Norwegian H.M. the King’s Gold medal for best PhD thesis in Medicine in the year 2016, being the first Italian researcher who has ever received it."


OUH researchers publish groundbreaking computer tools for cell biology research in Nature Methods


A group at the Department of Immunology at OUH has developed software tools that help solving one of the biggest challenges in large-scale protein analysis, or proteomics. In an article published in prestigious Nature Methods (journal impact factor 32.1) they show that Microsoft Excel can be applied to align large datasets from multiple studies and obtain a better picture of how cells are wired.


POLE proofreading domain mutations identify a subset of immunogenic colorectal cancers with excellent prognosis

Ragnhild A. Lothe and Arild Nesbakken
Ragnhild A. Lothe and Arild Nesbakken

A multicentre biomarker study, including data from the research teams of professors Ragnhild A. Lothe and Arild Nesbakken at the K.G.Jebsen Colorectal Cancer Research Centre, OUH, was recently published in Lancet Gastroenterology & Hepatology.
A small subgroup of patients with exceptionally mutated (ultramutated) cancers caused by mutations that impair DNA polymerase epsilon (POLE) proofreading are shown to have excellent prognosis.


Clinical Cancer Research highlights biomarker paper from Lyng’s group

Christina Sæten Fjeldbo (first author)
Christina Sæten Fjeldbo (first author)

Molecular targeting of tumor hypoxia is a promising strategy for improving the radiotherapy of cervical cancer. A biomarker for classifying patients according to hypoxia is, however, lacking and is an important requirement for reliable drug evaluation and to avoid added toxicity to patients with no expected benefit.
In a study published in Clinical Cancer Research (journal impact factor 8.7), postdoc Christina S. Fjeldbo (photo) in Lyng’s group and colleagues at Oslo University Hospital and Aarhus University Hospital present a hypoxia classifier that is reflected in diagnostic DCE-MR images and based on the expression level of six genes in a biopsy.